On the evening of April 19, METAi Therapeutics successfully cleared the hearing process and is now gearing up for a listing on the Hong Kong Stock Exchange under the 18C regulations, with a vision to emerge as the 'pioneer AI drug delivery stock.' Despite its relatively nascent entrepreneurial journey, constrained financing, and a compact workforce, METAi Therapeutics has positioned itself at the forefront of the industry through its remarkable research and development advancements. The company capitalized on the shift in innovative drug R&D from the 'era of targets' to the 'era of delivery,' unveiling the world's pioneering AI nano-delivery platform, NanoForge, in September 2025. Since then, its investments in innovation have started to bear fruit, with the creation of multiple delivery systems tailored for specific organs or tissues. Leveraging NanoForge, the company has introduced three key professional solutions and boasts a product pipeline exceeding 10 items. Among these, the most advanced MTS-004 bridges the gap in domestic PBA therapeutic drugs, while MTS-105 is on track to become the world's inaugural mRNA-encoded TCE solid tumor therapy. METAi Therapeutics has adopted a dual-pronged business model of 'platform collaboration + product collaboration,' achieving a revenue milestone of over RMB 100 million in 2025, coupled with a reduction in losses and enhanced gross margins. Following its listing on the Hong Kong Stock Exchange, METAi Therapeutics intends to allocate the raised funds towards platform technology upgrades, pipeline clinical trials, the development of animal health and anti-aging solutions, as well as pursuing collaborations and investments. Its future trajectory is indeed promising and eagerly awaited.